• ##navigation.register##
  • ##navigation.login##
    • en
    • uz
    • ru
  • en
  • uz
  • ru
##navigation.register## ##navigation.login##
  • Joriy
  • ##navigation.archives##
    • ##about.aboutContext##
    • ##about.submissions##
    • ##common.editorialMasthead##
    • ##manager.setup.privacyStatement##
    • ##about.contact##
Joriy ##navigation.archives##
##about.aboutContext## ##about.submissions## ##common.editorialMasthead## ##manager.setup.privacyStatement## ##about.contact##
  1. ##common.homepageNavigationLabel##
  2. ##common.search##

##common.search##

##search.advancedFilters##
##search.dateFrom##
##search.dateTo##

##search.searchResults##

##search.searchResults.foundPlural##
  • MICROVASCULAR REMODELING AND THE ENDOTHELIAL-APOPTOTIC SWITCH IN LICHEN SCLEROSUS: AN IMMUNOHISTOCHEMICAL STAGE-BASED STUDY

    Omasharifa binti Jamal Po##common.commaListSeparator##Sidikov A.A.

    Purpose: To evaluate stage-specific microvascular and apoptotic changes in lichen sclerosus (LS) using CD31, VEGF and CD95 immunohistochemistry. Methods: The article is based on a dissertation cohort of 60 patients with LS. For stage-oriented immunohistochemical analysis, representative dermal samples from progressive-stage lesions (n=15) and chronic-stage lesions (n=15) were examined. Results: In progressive-stage LS, dermal CD31 expression was detected in 33% of samples, VEGF in 80%, and CD95 in 20%, while all three markers were absent in the epidermis. In chronic-stage LS, dermal CD31 expression was present in 53%, VEGF in 20%, and CD95 in 95% of samples, again with no epidermal expression. Morphologically, progressive-stage lesions showed vacuolar interface dermatitis, lymphocytic exocytosis and lichenoid inflammation, whereas chronic-stage lesions were dominated by papillary dermal fibrosis and sclerosis. Malignant progression to squamous cell carcinoma (SCC) was documented in 5 of 60 patients and was associated with ulceration, bleeding, proliferating irregular vessels, epithelial atypia, pathological mitoses and high CD95 expression. Conclusion: LS demonstrates a stage-dependent shift from endothelial activation and neoangiogenesis to endothelial injury, apoptotic remodeling and sclerosis. Combined clinicopathological and immunohistochemical assessment may improve early recognition of unfavorable disease evolution.

    72-75
    11-06-2026
    Davomini o‘qing
  • MICROVASCULAR REMODELING AND THE ENDOTHELIAL-APOPTOTIC SWITCH IN LICHEN SCLEROSUS: AN IMMUNOHISTOCHEMICAL STAGE-BASED STUDY

    Po O.J.##common.commaListSeparator##Sidikov A.A.

    Purpose: To evaluate stage-specific microvascular and apoptotic changes in lichen sclerosus (LS) using CD31, VEGF and CD95 immunohistochemistry. Methods: The article is based on a dissertation cohort of 60 patients with LS. For stage-oriented immunohistochemical analysis, representative dermal samples from progressive-stage lesions (n=15) and chronic-stage lesions (n=15) were examined. Results: In progressive-stage LS, dermal CD31 expression was detected in 33% of samples, VEGF in 80%, and CD95 in 20%, while all three markers were absent in the epidermis. In chronic-stage LS, dermal CD31 expression was present in 53%, VEGF in 20%, and CD95 in 95% of samples, again with no epidermal expression. Morphologically, progressive-stage lesions showed vacuolar interface dermatitis, lymphocytic exocytosis and lichenoid inflammation, whereas chronic-stage lesions were dominated by papillary dermal fibrosis and sclerosis. Malignant progression to squamous cell carcinoma (SCC) was documented in 5 of 60 patients and was associated with ulceration, bleeding, proliferating irregular vessels, epithelial atypia, pathological mitoses and high CD95 expression. Conclusion: LS demonstrates a stage-dependent shift from endothelial activation and neoangiogenesis to endothelial injury, apoptotic remodeling and sclerosis. Combined clinicopathological and immunohistochemical assessment may improve early recognition of unfavorable disease evolution.

    40-43
    16-05-2026
    Davomini o‘qing
##navigation.items##

Ma'lumot

  • ##navigation.infoForReaders##
  • Mualliflar uchun
  • Kutubxonachilar uchun

So'nggi nashrlar

  • Atom logotipi
  • RSS2 logotipi
  • RSS1 logotipi
TNMU Publishing

Biz tibbiyotning rivojlanishini tezlashtirish va jamiyat salomatligini yaxshilash uchun tadqiqotchilar, bilim va texnologiyalarni birlashtiramiz.

 

Navigatsiya

Bosh sahifa
Jurnallar
Konferensiyalar
Mualliflar
Taqrizchilar
Nashriyot xizmatlari

Madad

Ijodkor qoidalari
Nashr axloqi
Biz haqimizda
Savol-javob
Qayta aloqa

Kontaktlar

 
O‘zbekiston, Toshkent,,
Olmazor tumani, Shifokorlar ko‘chasi, 21-uy
 
(+998) 91 164 24 40
 
publishing@tnmu.uz
© Copyright 2026 TNMU Publishing All Rights Reserved | Developed by in Science | Site create by in Designer
##user.login##
Central Asian Journal of Medicine
##user.login##
* ##common.required##
* ##common.required##
##user.login.forgotPassword##
##user.login.rememberUsernameAndPassword##
##user.login.registerNewAccount##